NEW YORK, July 29, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports
highlighting WellPoint Inc. (NYSE: WLP), Thermo Fisher Scientific,
Inc. (NYSE: TMO), Varian Medical Systems Inc. (NYSE: VAR),
Medicines Co. (NASDAQ: MDCO), and Forest Laboratories Inc. (NYSE:
FRX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings
- via the links below.
WellPoint Inc. Research Report
On July 24, 2013, WellPoint Inc.
(WellPoint) announced its Q2 2013 financial results with net income
of $800.1 million or $2.64 per share, compared with $643.6 million or $1.94 per share in Q2 2012. Adjusted net income
was $2.60 per share, reflecting a
27.5% YoY increase. "We are pleased with our second quarter results
and encouraged by the positive momentum we have across the
organization. Our Commercial businesses continue to perform well
and we have achieved improvements in our Medicaid operations,
largely reflecting benefits from the Amerigroup transaction," said
Joseph Swedish, Chief Executive Officer. "Looking ahead, we
continue to actively prepare for the coming marketplace changes,
and believe we are well-positioned for the significant growth
opportunities on the horizon. We're also seeing improving trends in
the Local Group and National Account ASO markets, and expect
membership growth from those areas next year." The Company now
anticipates full-year 2013 net income to be at least $8.00 per share, on both a GAAP and Adjusted
basis. The Full Research Report on WellPoint Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/64cd_WLP]
Thermo Fisher Scientific, Inc.
Research Report
On July 24, 2013, Thermo Fisher
Scientific Inc. (Thermo Fisher)
announced its Q2 FY 2013 financial results (period ended
June 29, 2013), posting revenue
growth of 4.2% YoY to $3.2 billion.
Adjusted EPS grew 8.2% YoY to $1.32.
The Company's operating margin expanded 30 basis points to 19.3%.
Marc N. Casper, President and Chief
Executive Officer of Thermo Fisher
said, "It was a stand-out quarter for innovation. We unveiled three
new-generation Thermo Scientific platforms to provide a broad set
of customers with exceptional levels of performance, speed and ease
of use. We also continued to strengthen our R&D capabilities in
Asia-Pacific by establishing our
new China Innovation Center in Shanghai - another example of our focus on
innovating to meet our customers' needs." Thermo Fisher updated its full-year FY 2013
revenue guidance in the range of $12.8
billion to $13 billion. The Full Research Report on Thermo
Fisher Scientific, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.analystscorner.com/r/full_research_report/45ed_TMO]
Varian Medical Systems Inc. Research
Report
On July 24, 2013, Varian Medical
Systems (Varian) announced its Q3 FY 2013 financial results (period
ended June 28, 2013) posting net
earnings of $1.03 per diluted share,
a 7.3% YoY growth. Revenues totaled $726.2
million for the quarter, up 3% YoY. "Varian's net earnings
rose versus the year-ago quarter in line with expectations while
revenues rose somewhat less than expected due primarily to a
significant currency headwind with the Yen as well as inventory
adjustments among major X-ray tube customers in Japan," said Dow R. Wilson, Varian Medical
Systems' CEO. The Company anticipates a 5% YoY growth on Company
revenues for full-year FY 2013, with net earnings per diluted share
in the range of $4.00 to $4.04. The
Full Research Report on Varian Medical Systems Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/bd48_VAR]
Medicines Co. Research Report
On July 24, 2013, The Medicines
Company announced its Q2 2013 financial results with net revenue
growth of 27.3% YoY to $172.8
million. Net income attributable to the Company totaled
$18.1 million or $0.30 per share compared with net income of
$13.8 million or $0.25 per share in Q2 2012. Adjusted net income
increased 62.2% YoY to $29.2 million
or $0.50 per share. Glenn Sblendorio, President and CFO of The
Medicines Company, stated, "Our first half 2013 revenues show a
continued diversification of growth sources, as our hospital
portfolio and global geographies expand. Additionally, our near
term anticipated growth drivers advanced significantly in the
second quarter, as we reported positive Phase 3 results of the
oritavancin Phase 3 SOLO II trial, filed for US approval for
cangrelor, and completed clinical work toward filings for IONSYS."
The Full Research Report on Medicines Co. - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/5a84_MDCO]
Forest Laboratories Inc. Research
Report
On July 23, 2013, Forest
Laboratories Inc. (Forest Laboratories) announced its Q1 FY 2014
financial results posting diluted EPS of $0.09 compared to $0.21 in Q1 FY 2013. According to the Company,
non-GAAP EPS excluding acquisition related amortization and
specified items remained flat YoY at $0.28 in Q1 FY 2014. The Company's net sales
increased 6.0% YoY to $796.9 million
driven by the Company's next generation products. Howard Solomon, Chairman and CEO of Forest
Laboratories, said, "We are very pleased with the financial results
for the quarter and particularly with the significant percentage
increases in the sales of almost all of our new products and with
the initial response to Linzess and Tudorza which
were both launched this past December. Collectively, our next
generation products had sales of $294.1
million in the quarter, representing 47.8% growth in
comparison to the comparable prior year quarter." The Full Research
Report on Forest Laboratories Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ea24_FRX]
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
http://www.AnalystsCorner.com
SOURCE Analysts' Corner